Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Individuals Aged 2 Years and Older
CTR20150850Phase 3Completed
- Sponsor
- Lanzhou Institute of Biological Products Co., Ltd.
- Start
- Dec 2015
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of 23-valent pneumococcal polysaccharide vaccine in pneumococcal disease, sponsored by Lanzhou Institute of Biological Products Co., Ltd.. Started Dec 2015; status: completed.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on CTR20150850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150850.